BRCA1-Associated Protein 1 in Sarcoma
- 1Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR 97213, USA
- 2Department of Respiratory and Critical Care Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong Hospital of Fudan University, Shanghai 201399, China
Abstract
Soft tissue sarcomas (STSs) are genetically complex mesenchymal tumors with limited therapeutic options. BRCA1-associated protein 1 (BAP1), a deubiquitinase, is a critical regulator of chromatin architecture, DNA repair, and cell cycle control. While BAP1 alterations are well-characterized in mesothelioma and uveal melanoma, their role in STS remains understudied. Increasing evidence shows BAP1 alterations are associated with STS. This review summarizes current evidence on BAP1 biology and its emerging significance in sarcoma. We discuss BAP1’s molecular functions, including its role in the Polycomb Repressive Deubiquitinase (PR-DUB) complex, and summarize recent findings implicating BAP1 loss in multiple subtypes of STS. We highlight mechanistic links between BAP1 deficiency, genomic instability, and tumor progression, and explore therapeutic implications such as polo-like kinase 1 (PLK1) inhibition and epigenetic modulation. Understanding BAP1-driven pathways in STS may uncover novel biomarkers and targeted strategies, addressing a critical unmet need in sarcoma management.
Related
- Cell-of-origin shapes tumor subtype in BRCA1-associated triple-negative breast cancer
- PFN1 inhibits lytic replication of Kaposi sarcoma-associated herpesvirus through SQSTM1/p62-mediated selective autophagy targeting the KSHV helicase
- Presumed myofibroblastic hepatic sarcoma associated with a retained surgical swab in a 3.5-year-old dog
- Characterization of plasma TNFRSF/TNFSF molecule profiles in HIV-associated disseminated Kaposi’s sarcoma over short- and long-term follow-up
- Somatic and Germline Telomere Biology in Sarcoma: Telomere Maintenance Is Acquired at Liposarcoma Dedifferentiation, and Genetically Longer Telomeres Are Associated With Liposarcoma Risk
BibTeX
@article{liu2026brca1associated,
title = {{BRCA1-Associated Protein 1 in Sarcoma}},
author = {Xingliang Liu and William Haugh and Ziqiang Zhang and Jianguo Huang},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18213496},
url = {https://www.mdpi.com/2072-6694/18/21/3496},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - BRCA1-Associated Protein 1 in Sarcoma
AU - Xingliang Liu
AU - William Haugh
AU - Ziqiang Zhang
AU - Jianguo Huang
PY - 2026
DA - 2026/10/30
JO - Cancers
DO - 10.3390/cancers18213496
UR - https://www.mdpi.com/2072-6694/18/21/3496
AB - Soft tissue sarcomas (STSs) are genetically complex mesenchymal tumors with limited therapeutic options. BRCA1-associated protein 1 (BAP1), a deubiquitinase, is a critical regulator of chromatin architecture, DNA repair, and cell cycle control. While BAP1 alterations are well-characterized in mesothelioma and uveal melanoma, their role in STS remains understudied. Increasing evidence shows BAP1 alterations are associated with STS. This review summarizes current evidence on BAP1 biology and its emerging significance in sarcoma. We discuss BAP1’s molecular functions, including its role in the Polycomb Repressive Deubiquitinase (PR-DUB) complex, and summarize recent findings implicating BAP1 loss in multiple subtypes of STS. We highlight mechanistic links between BAP1 deficiency, genomic instability, and tumor progression, and explore therapeutic implications such as polo-like kinase 1 (PLK1) inhibition and epigenetic modulation. Understanding BAP1-driven pathways in STS may uncover novel biomarkers and targeted strategies, addressing a critical unmet need in sarcoma management.
SN - 2072-6694
ER -